Understanding Adverse Events in Multiple Myeloma
Nina Shah, MD, discussed how adverse events impact treatment decision-making for patients with multiple myeloma.
EP: 1.Breakthroughs in Therapeutic Options for Relapsed/Refractory Multiple Myeloma
EP: 2.Highlights From the 2021 European Hematology Association Congress on Multiple Myeloma
EP: 3.Upcoming Abstracts on Multiple Myeloma for Presentation at 2021 ASH
EP: 4.Biggest FDA News for Multiple Myeloma in 2021
EP: 5.Treatment Options for Transplant-Eligible Multiple Myeloma
EP: 6.Treatment Options for Transplant-Ineligible Multiple Myeloma
EP: 7.Navigating Individual Treatment for Relapsed/Refractory Multiple Myeloma
EP: 8.Understanding Adverse Events in Multiple Myeloma
EP: 9.BCMA-Directed Agents for Multiple Myeloma
EP: 10.Optimal Therapies for Relapsed/Refractory Multiple Myeloma
EP: 11.Emerging Research and Therapies for Multiple Myeloma
EP: 12.Upcoming Phase 3 Data in Multiple Myeloma
EP: 13.Trials Evaluating Emerging Maintenance Therapy Regimens in Multiple Myeloma
EP: 14.Looking Ahead to the Future of Multiple Myeloma Treatment
EP: 15.Current Leading Therapies for Multiple Myeloma
Nina Shah, MD: Understanding the adverse events from these particular studies and what has happened is important to understand what you’re going to choose for your patients. This is one of the other parts of myeloma decision making. It’s not just how well they’re going to do, but how poorly they won’t do. Meaning if you know your patient has a poor cardiovascular status, you’re not going to give them something that could potentially drop their blood pressure. For example, that person should not get a CAR T-cell therapy because there’s a very high chance that the person would has cytokine release syndrome [CRS] could also have low blood pressure. There are also patients who have renal insufficiency, and they cannot get conditioning chemotherapy with fludarabine and also cannot get CAR T-cell therapy. On the whole, giving yourself information, being educated, and giving the patients a lot of information—which is actually available very nicely from all the presentations—at least sets expectations. If the patients know that there’s a chance they’re going to have a fever with these novel regimens, they may have low blood pressure, they may have low blood counts, which is something that we expect for a lot of different agents in multiple myeloma, but at least these expectations are set and then these can be managed and mitigated sometimes by things like close monitoring. Grade 1 CRS can be addressed with things like tocilizumab [Actemra]. Ultimately, what you know is the adverse event pattern should be one of the major pathways that helps you guide how to choose which medication for each particular patient.
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
